Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 391 participants.
Also called NCT06221371
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 391 participants
- Registry
-
NCT06221371
-
- Other papers using this trial's data
- Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06221371. Randomized; single masking; primary purpose treatment. Start 2024-01-25 (actual); primary completion 2025-10-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion
- Acronym
- TNK-PLUS
- Condition
- Ischemic Stroke, Acute
- Condition
- Thrombolysis
- Condition
- Endovascular Treatment
- Intervention (Drug)
- Tenecteplase
- Intervention (Device)
- direct EVT
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Linyi People's Hospital
Record details
- Record id
cardio:ct-nct06221371- Content hash
22ad962136ece4c59643075fc9070317a9ca7c692ecf846c4df35e3a30621ff0